Litigation Details for Genzyme Corporation v. Genentech, Inc. (C.D. Cal. 2015)
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Genzyme Corporation v. Genentech, Inc. (C.D. Cal. 2015)
| Docket | See Plans and Pricing | Date Filed | 2015-12-29 |
| Court | District Court, C.D. California | Date Terminated | 2016-08-19 |
| Cause | 28:1338 Patent Infringement | Assigned To | George H. Wu |
| Jury Demand | Both | Referred To | Alicia G. Rosenberg |
| Patents | 10,004,237 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Genzyme Corporation v. Genentech, Inc.
The biologic drug covered by the patent cited in this case is See Plans and Pricing .
Details for Genzyme Corporation v. Genentech, Inc. (C.D. Cal. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-07-01 | 77 | alterations, deletions or additions[.]’” ECF No. 75-10 at 4 (237). 19 With respect to changes in the amino …antibody.” Cabilly 19 III Patent at 6:66-7:1 (53-54), ECF No. 75-3. The patent contemplates that “[c]hanges…takes issue with the assertion that the Cabilly III patent claims cover 16 Genzyme’s product Lemtrada® in…royalties on that antibody under the Cabilly III patent without suggesting that 19 Genzyme did not require…constant region. See 26 1 The Cabilly III patent issued on April 12, 2011. Lemtrada® was approved | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
